Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Status Completed

Clinical Trial Summary

This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine whether selection of the optimal IFN-alpha-2b (recombinant interferon alfa-2b) dose can be made using signal transduction data.

SECONDARY OBJECTIVES:

I. To determine the tolerability of adjuvant IFN-alpha-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.

II. The transcription of a panel of IFN-alpha-induced genes previously identified by microarray analysis will be determined by Real-Time reverse transcriptase-polymerase chain reaction (RT PCR) in order that the correlation between signal transducer and activator of transcription 1 (STAT1) phosphorylation and IFN-alpha gene regulation can be evaluated.

III. Microarray analysis of patient peripheral blood mononuclear cells (PBMCs) will be used to evaluate the effect of dose-reduction on IFN-alpha gene expression.

IV. In order to define the clinical role of tumor sensitivity to IFN-alpha, patient tumor biopsies taken prior to the administration of IFN-alpha will be systematically evaluated for cellular levels of janus kinase (Jak)-STAT signaling intermediates.

OUTLINE:

Patients receive recombinant interferon alfa-2b subcutaneously (SC) thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3-6 months for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01460875
Study type	Interventional
Source	Ohio State University Comprehensive Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	April 22, 2008
Completion date	January 5, 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01886235` - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery	N/A
Completed	`NCT01961115` - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Phase 2
Completed	`NCT02858869` - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Phase 1
Completed	`NCT03229278` - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Phase 1
Completed	`NCT01989559` - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery	Phase 1
Withdrawn	`NCT02812693` - Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification	Phase 1/Phase 2
Completed	`NCT00026221` - Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	Phase 2
Active, not recruiting	`NCT02876068` - Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	Phase 1
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00397982` - Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma	Phase 2
Terminated	`NCT01744171` - Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma	Phase 1
Terminated	`NCT02748564` - Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	Phase 2
Completed	`NCT02941744` - A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases	Phase 1/Phase 2
Completed	`NCT01789827` - Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy	Early Phase 1
Terminated	`NCT01970527` - Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma	Phase 2
Active, not recruiting	`NCT02654821` - Study With T-cel Receptor Gene Therapy in Metastatic Melanoma	Phase 1/Phase 2
Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
Completed	`NCT00866177` - MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma	Phase 2
Active, not recruiting	`NCT03719131` - Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy	Phase 2
Completed	`NCT02716948` - SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine	Phase 1